LAUSANNNE, Switzerland and CHIBA, Japan, October 31 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, and NanoCarrier Co., Ltd. (NanoCarrier) today announced the signature of a License and Supply Agreement for DACH-Platin Polymeric Micelle (Debio 0507/NC-4016), MediCelle(TM) technology, owned by NanoCarrier, currently in late preclinical development by Debiopharm for use in oncology. Phase I clinical studies are expected to start in 2008 in Europe and / or USA.
Under the terms of the agreement:
- NanoCarrier grants Debiopharm an exclusive license, with the right to sublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwide excluding Japan.
- Debiopharm will provide NanoCarrier exclusively with the starting material of DACH-platin, and NanoCarrier will manufacture and provide DACH-Platin Polymeric Micelle solely to Debiopharm.
- Debiopharm will cover costs related to the manufacture of DACH-Platin Polymeric Micelle and will pay NanoCarrier an up-front and milestones, as well as running royalties for the license.
- NanoCarrier will pay Debiopharm for the use of Debiopharm's data or intellectual property upon registration in Japan.
Debiopharm will be fully responsible for the development of DACH-Platin Polymeric Micelle. The collaboration between the two companies started in 2005, when NanoCarrier granted Debiopharm the exclusive option to license-in a DACH-platin-PEG-polyglutamic acid (DACH Platin MediCelle(TM)) from NanoCarrier, for use in oncology.
About DACH-Platin Micelle
DACH-platin is an active metabolite of Oxaliplatin, which shows
stronger anticancer activity. Oxaliplatin is an anticancer drug effective
against progressive and relapsed colon cancer. However, it may cause severe
peripheral neuropathy like numbness. Because of its hydrophobic feature, it
was difficult to formulate DACH-pl
|SOURCE The Debiopharm Group|
Copyright©2007 PR Newswire.
All rights reserved